Pharmacovigilance Market Size, Share & Industry Analysis
| 出版社 | Fortune Business Insights |
| 出版年月 | 2024年9月 |
| ページ数 | 113 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,850 |
| 種別 | 英文調査報告書 |
Growth Factors of Pharmacovigilance (PV) Market
The pharmacovigilance (PV) market size was valued at USD 7.42 billion in 2023, and the market is now projected to grow from USD 8.32 billion in 2024 to USD 23.45 billion by 2032, exhibiting a CAGR of 13.8 13.8% during the forecast period of 2024-2032.
ファーマコビジランス（PV）市場規模は2023年に74億2,000万米ドルと評価されており、現在市場は2024年の83億2,000万米ドルから2032年までに234億5,000万米ドルに成長すると予測されており、2024-2032年の予測期間中に13.8～13.8％のCAGRを示しています。
The global pharmacovigilance (PV) market growth due to COVID-19 in 2020 increased the popularity of service and better aspects of drug safety data. With higher rates of clinical trials and vaccines, major players experienced revenue increases in years 2021. Drug safety monitoring increased over the years as an aspect of product sales by 2022. Therefore, consistent research and development investments and new product launches in the drugs and vaccines segment will drive the markets’ growth from 2024 to 2032.
Increasing knowledge among global citizens and healthcare practitioners on ADR reporting has the added effect of improving the market growth as the patients and physicians report better. Preliminary campaigns including the MedSafety Week held in November 2023 ensure that people receive information on medication safety and reporting side effects. These activities are anticipated to contribute towards the growth of the global pharmacovigilance (PV) market share.
Furthermore, the application of AI in pharmacovigililation improves the process of drug safety reporting because the AI-based tool can look for an adverse event in large amounts of data. AI enhances effectiveness by redirecting PV professionals’ tasks involving value, thus providing better tools for decision-making. This strategy is being adopted by major players as more solution providers offer artificial intelligence solutions making the market broader.
Comprehensive Analysis of Pharmacovigilance (PV) Market
Due to its ability to segment the market, the pharmacovigilance (PV) market and healthcare industry have significant growth rates in its current period. This market expansion could also offer a comprehensive regional overview concerning the supply and demand dynamics affecting the pharmaceuticals market. Such segmentations are carried out systematically in a manner that separates them by type, by deployment and by end user. The type include, Service and Software. The deployment include, In-house and Outsource. However, the end users include, Contract Research Organizations (CROs), Pharmaceutical & Biotechnfology Companies, and Others.
North America had the largest market share and it could reach USD 3.01 billion in 2023. The region stands as the market leader due to the large market size of pharmaceuticals, high spending on health, well-developed infrastructure and ranked market participants with modern services and software for monitoring drug safety. Also, the increase in the number of regulations, especially in the U.S., will help propel the demand for these services. Furthermore, the expansion of the emerging players in the specific region for service provision will also augment the development of the region.
The key players in the market are involved in the healthcare industry to guarantee industrial prospectus growth and to determine market trends. These players include, IQVIA Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.), Parexel International Corporation (U.S.), Accenture (Ireland), Cognizant (U.S.), Ergomed Group (U.K.), Thermo Fisher Scientific Inc. (Pharmaceutical Product Development, LLC) (U.S.), ICON plc (Ireland), and Quanticate (U.K.). These market players ensure that there is a level playing ground for the competition.
In February 2024, A newly launched technology platform named PrimeVigilance of Ergomed plc a global PV and regulatory service provider bought Panacea to expand the company’s operations in PV, regulatory affairs, QA, auditing and support solutions for the pharmaceutical, biotech and med-device industries.
Segmentation Table
Global Pharmacovigilance (PV) Market Scope
Study Period 2019-2032
Base Year 2023
Forecast Period 2024-2032
Growth Rate CAGR of 13.8% from 2024-2032
Historical Period 2019-2022
Unit Value (USD Billion)
Segmentation By Type, Deployment, End-user, and Region
By Type • Service
• Software
By Deployment • In-house
• Outsource
By End-user • Contract Research Organizations (CROs)
• Pharmaceutical & Biotechnology Companies
• Others
By Region • North America (By Type, Deployment, End-User, and Country)
o U.S. (By Type)
o Canada (By Type)
• Europe (By Type, Deployment, End-User, and Country/Sub-Region)
o Germany (By Type)
o U.K. (By Type)
o France (By Type)
o Italy (By Type)
o Spain (By Type)
o Rest of Europe (By Type)
• Asia Pacific (By Type, Deployment, End-User, and Country/Sub-Region)
o China (By Type)
o Japan (By Type)
o India (By Type)
o Australia (By Type)
o Southeast Asia (By Type)
o Rest of Asia Pacific (By Type)
• Latin America (By Type, Deployment, End-User, and Country/Sub-Region)
o Brazil (By Type)
o Mexico (By Type)
o Rest of Latin America (By Type)
• Middle East and Africa (By Type, Deployment, End-User, and Country/Sub-Region)
o GCC (By Type)
o South Africa (By Type)
o Rest of the Middle East & Africa (By Type)
Table of Contents
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Key Insights
4.1. Snapshot of Rate of Adverse Drug Reactions – By Key Region/Countries
4.2. Regulatory Scenario in the Pharmacovigilance Industry
4.3. Overview of Government Initiatives in Safe Medicine Use
4.4. Key Industry Developments (Mergers, Acquisitions, Collaborations, etc.)
4.5. Impact of COVID-19 on the Market
5. Global Pharmacovigilance Market Analysis, Insights and Forecast, 2019-2032
5.1. Market Analysis, Insights and Forecast – By Type
5.1.1. Service
5.1.2. Software
5.2. Market Analysis, Insights and Forecast – By Deployment
5.2.1. In-house
5.2.2. Outsource
5.3. Market Analysis, Insights and Forecast – By End User
5.3.1. Contract Research Organizations (CROs)
5.3.2. Pharmaceutical & Biotechnology Companies
5.3.3. Others
5.4. Market Analysis, Insights and Forecast – By Region
5.4.1. North America
5.4.2. Europe
5.4.3. Asia Pacific
5.4.4. Latin America
5.4.5. Middle East & Africa
6. North America Pharmacovigilance Market Analysis, Insights and Forecast, 2019-2032
6.1. Market Analysis, Insights and Forecast – By Type
6.1.1. Service
6.1.2. Software
6.2. Market Analysis, Insights and Forecast – By Deployment
6.2.1. In-house
6.2.2. Outsource
6.3. Market Analysis, Insights and Forecast – By End User
6.3.1. Contract Research Organizations (CROs)
6.3.2. Pharmaceutical & Biotechnology Companies
6.3.3. Others
6.4. Market Analysis, Insights and Forecast – By Country
6.4.1. U.S.
6.4.1.1. By Type
6.4.2. Canada
6.4.2.1. By Type
7. Europe Pharmacovigilance Market Analysis, Insights and Forecast, 2019-2032
7.1. Market Analysis, Insights and Forecast – By Type
7.1.1. Service
7.1.2. Software
7.2. Market Analysis, Insights and Forecast – By Deployment
7.2.1. In-house
7.2.2. Outsource
7.3. Market Analysis, Insights and Forecast – By End User
7.3.1. Contract Research Organizations (CROs)
7.3.2. Pharmaceutical & Biotechnology Companies
7.3.3. Others
7.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
7.4.1. Germany
7.4.1.1. By Type
7.4.2. U.K.
7.4.2.1. By Type
7.4.3. France
7.4.3.1. By Type
7.4.4. Italy
7.4.4.1. By Type
7.4.5. Spain
7.4.5.1. By Type
7.4.6. Rest of Europe
7.4.6.1. By Type
8. Asia Pacific Pharmacovigilance Market Analysis, Insights and Forecast, 2019-2032
8.1. Market Analysis, Insights and Forecast – By Type
8.1.1. Service
8.1.2. Software
8.2. Market Analysis, Insights and Forecast – By Deployment
8.2.1. In-house
8.2.2. Outsource
8.3. Market Analysis, Insights and Forecast – By End User
8.3.1. Contract Research Organizations (CROs)
8.3.2. Pharmaceutical & Biotechnology Companies
8.3.3. Others
8.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
8.4.1. China
8.4.1.1. By Type
8.4.2. Japan
8.4.2.1. By Type
8.4.3. India
8.4.3.1. By Type
8.4.4. Australia
8.4.4.1. By Type
8.4.5. Southeast Asia
8.4.5.1. By Type
8.4.6. Rest of Asia Pacific
8.4.6.1. By Type
9. Latin America Pharmacovigilance Market Analysis, Insights and Forecast, 2019-2032
9.1. Market Analysis, Insights and Forecast – By Type
9.1.1. Service
9.1.2. Software
9.2. Market Analysis, Insights and Forecast – By Deployment
9.2.1. In-house
9.2.2. Outsource
9.3. Market Analysis, Insights and Forecast – By End User
9.3.1. Contract Research Organizations (CROs)
9.3.2. Pharmaceutical & Biotechnology Companies
9.3.3. Others
9.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
9.4.1. Brazil
9.4.1.1. By Type
9.4.2. Mexico
9.4.2.1. By Type
9.4.3. Rest of Latin America
9.4.3.1. By Type
10. Middle East & Africa Pharmacovigilance Market Analysis, Insights and Forecast, 2019-2032
10.1. Market Analysis, Insights and Forecast – By Type
10.1.1. Service
10.1.2. Software
10.2. Market Analysis, Insights and Forecast – By Deployment
10.2.1. In-house
10.2.2. Outsource
10.3. Market Analysis, Insights and Forecast – By End User
10.3.1. Contract Research Organizations (CROs)
10.3.2. Pharmaceutical & Biotechnology Companies
10.3.3. Others
10.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
10.4.1. GCC
10.4.1.1. By Type
10.4.2. South Africa
10.4.2.1. By Type
10.4.3. Rest of Middle East & Africa
10.4.3.1. By Type
11. Competitive Analysis
11.1. Global Market Share Analysis (2023)
11.2. Company Profiles
11.2.1. IQVIA Inc.
11.2.1.1. Overview
11.2.1.2. Products & Services
11.2.1.3. SWOT Analysis
11.2.1.4. Recent Developments
11.2.1.5. Strategies
11.2.1.6. Financials (Based on Availability)
11.2.2. Labcorp Drug Development
11.2.2.1. Overview
11.2.2.2. Products & Services
11.2.2.3. SWOT Analysis
11.2.2.4. Recent Developments
11.2.2.5. Strategies
11.2.2.6. Financials (Based on Availability)
11.2.3. Parexel International Corporation
11.2.3.1. Overview
11.2.3.2. Products & Services
11.2.3.3. SWOT Analysis
11.2.3.4. Recent Developments
11.2.3.5. Strategies
11.2.3.6. Financials (Based on Availability)
11.2.4. Accenture
11.2.4.1. Overview
11.2.4.2. Products & Services
11.2.4.3. SWOT Analysis
11.2.4.4. Recent Developments
11.2.4.5. Strategies
11.2.4.6. Financials (Based on Availability)
11.2.5. Cognizant
11.2.5.1. Overview
11.2.5.2. Products & Services
11.2.5.3. SWOT Analysis
11.2.5.4. Recent Developments
11.2.5.5. Strategies
11.2.5.6. Financials (Based on Availability)
11.2.6. Ergomed Group
11.2.6.1. Overview
11.2.6.2. Products & Services
11.2.6.3. SWOT Analysis
11.2.6.4. Recent Developments
11.2.6.5. Strategies
11.2.6.6. Financials (Based on Availability)
11.2.7. Thermo Fisher Scientific Inc. (Pharmaceutical Product Development, LLC)
11.2.7.1. Overview
11.2.7.2. Products & Services
11.2.7.3. SWOT Analysis
11.2.7.4. Recent Developments
11.2.7.5. Strategies
11.2.7.6. Financials (Based on Availability)
11.2.8. ICON plc.
11.2.8.1. Overview
11.2.8.2. Products & Services
11.2.8.3. SWOT Analysis
11.2.8.4. Recent Developments
11.2.8.5. Strategies
11.2.8.6. Financials (Based on Availability)
11.2.9. Quanticate
11.2.9.1. Overview
11.2.9.2. Products & Services
11.2.9.3. SWOT Analysis
11.2.9.4. Recent Developments
11.2.9.5. Strategies
11.2.9.6. Financials (Based on Availability)
Fortune Business Insights（フォーチュンビジネスインサイツ）は多様な産業を対象に市場調査を行い、市場動向、競争環境、将来予測などを盛り込んだ市場調査レポートを出版しています。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
| シングルユーザ | マルチユーザ | エンタープライズ |
| USD4,850 | USD5,850 | USD6,850 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス ※レポートタイトルにより異なる場合がございます。詳細はお問合せください。
- シングルユーザライセンス
- 提供ファイル：PDF（印刷不可）
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 提供ファイル：PDF（印刷不可）＋Excel（印刷不可）
- 同一企業内6名までレポートファイルのご共有が可能です。
- エンタープライズライセンス
- 提供ファイル：PDF（印刷可能）＋Excel（印刷可能）
- 同一企業内人数無制限でレポートファイルのご共有が可能です。
- シングルユーザライセンス
- 納品方法
- Eメール
- 納期
- レポートタイトルにより異なります。詳細はお気軽にお問い合わせください。
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはFortune Business Insightsの日本の販売代理店として、Fortune Business Insightsのレポートを取り扱っております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にSEMABIZまでご連絡ください。
最新調査レポート